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Abstract
Purpose Pathological parameters assessed on biopsies and resection specimens have a pivotal role in the diagnosis, prognosis 
and management of patients with renal cell carcinoma (RCC).
Methods A non-systematic literature search was performed, updated to January 2018, to identify key standards and contro-
versies in the pathological classification, grading and staging of RCC.
Results Although most RCCs exhibit characteristic morphology that enables easy categorisation, RCCs show considerable 
morphological heterogeneity and it is not uncommon for there to be difficulty in assigning a tumour type, especially with 
rarer tumour subtypes. The differentiation between benign and malignant oncocytic tumours remains a particular challenge. 
The development of additional immunohistochemical and molecular tests is needed to facilitate tumour typing, because of 
the prognostic and therapeutic implications, and to enable more reliable identification of poorly differentiated metastatic 
tumours as being of renal origin. Any new tests need to be applicable to small biopsy samples, to overcome the heterogene-
ity of renal tumours. There is also a need to facilitate identification of tumour types that have genetic implications, to allow 
referral and management at specialist centres. Digital pathology has a potential role in such referral practice.
Conclusion Much has been done to standardise pathological assessment of renal cell carcinomas in recent years, but there 
still remain areas of difficulty in classification and grading of these heterogeneous tumours.
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Introduction
Pathological parameters assessed on biopsies and resec-
tion specimens have a pivotal role in the diagnosis, prog-
nosis and management of patients with renal cell carcinoma 
(RCC). Standardisation of specimen handling and patho-
logical assessment is, therefore, critical to ensuring that 
the information contained within histopathology reports is 
accurate and consistent, for both diagnostic and research 
purposes. Although various local and national guidelines 
have been utilised in clinical practice for many years, several 
recent initiatives have done much to improve consistency 
at an international level, enabling pathologists to provide 
the high-quality information required. In 2016, the WHO 
published a fourth edition of its classification of urological 
tumours, which is the current internationally recommended 
system for typing of renal tumours [1]. The updated version 
of this ‘Blue book’ also provides epidemiological, clinical 
and pathological information on the wide range of renal 
tumours that may be encountered in clinical practice.
Methods
A non-systematic literature search was conducted using 
Medline. The reference lists of selected manuscripts were 
checked manually for eligible articles. The most contempo-
rary guidelines and relevant articles are included, updated 
to January 2018.
 * Anne Y. Warren 
 anne.warren@nhs.net
1 Department of Histopathology, Cambridge University 
Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK
2 School of Medicine, University of St Andrews, 
St Andrews KY16 9TF, UK
 World Journal of Urology
1 3
Results
Best practice guidelines
In 2012, the European Network of Uropathology (ENUP) 
published a survey of the practice of handling nephrectomy 
specimens by pathologists from 15 European countries [2]. 
This was followed in the same year by an International Soci-
ety of Urological Pathology (ISUP) consensus conference 
on renal tumour pathology in Vancouver. Members of the 
Society were asked to complete a pre-meeting questionnaire 
on all aspects of their practice of specimen handling and 
pathological reporting of renal tumours. The results were 
presented at the conference by a panel of experts and were 
discussed and voted upon to determine what should be con-
sidered best practice. Following this conference, a series of 
ISUP publications has provided valuable guidance on speci-
men handling, tumour typing, grading and assessment of 
prognostic factors [3–8]. Subsequently, ISUP guidance for 
pathologists on best practice for use of routine immunohis-
tochemistry in the assessment of renal cell tumours has also 
been published [9, 10].
In addition, the International Committee for Cancer 
Reporting (ICCR) has devised a series of international data-
sets for pathologists reporting tumour pathology, with the 
renal tumour datasets published in 2017 [11, 12]. In the UK, 
the third edition of the Royal College of Pathologists dataset 
for renal cancer reporting was published in 2017 [13]. Simi-
lar protocols are readily available from, for example, the Col-
lege of American Pathologists (www.cap.org) and the Royal 
College of Pathologists of Australasia (www.rcpa.edu.au). 
These datasets contain guidance on which evidence-based 
‘core’ pathological data items should always be included 
in histopathology reports, to provide the essential informa-
tion required for patient management. Other items are also 
recommended for reporting, but are considered ‘non-core’ 
optional data at present due to insufficient evidence of their 
prognostic significance.
Pathological parameters and stage
The main core items included in renal tumour pathology 
reports, currently deemed essential for patient management, 
are discussed below.
Tumour type
The 2016 WHO classification of renal tumours is based on 
a combination of morphological, molecular and genetic fea-
tures [1]. RCCs represent the most common renal tumour in 
adults and are divided into a number of different histological 
types. The most common is the clear cell type (70–90%), 
followed by papillary (10–15%) and chromophobe RCCs 
(3–5%). Many studies, including large multicentre studies, 
have shown that tumour type has prognostic significance [6, 
14–20]. Tumour type also has utility in selection of patients 
for adjuvant therapy, further underlining the importance 
of assigning tumours to the correct category on pathologi-
cal assessment [21]. The major tumour types are discussed 
below, with their key pathological features, as well as rarer 
tumours that have differing clinical significance and may 
cause diagnostic difficulty.
Clear cell RCC has a worse prognosis than papillary or chro-
mophobe RCCs, when matched for stage, and is more likely 
to present at an advanced stage or with existing metastases 
[20, 22–24]. In 90% of cases, these tumours exhibit altera-
tions in the von Hippel–Lindau tumour suppressor (VHL) 
gene on chromosome 3 [25]. Most tumours are sporadic, but 
multiple bilateral tumours are seen in von Hippel–Lindau 
syndrome, a rare autosomal dominant condition also associ-
ated with a variety of other tumours that include haeman-
gioblastomas of the retina and central nervous system [26]. 
Multifocal sporadic tumours are rare and a recent study has 
shown that apparent multifocality may be due to retrograde 
venous invasion from a single tumour [27]. Grossly, clear 
cell RCCs characteristically contain solid yellow areas with 
variable amounts of cystic change, haemorrhage and necro-
sis. Although on microscopy they are classically composed 
of clear cells set within a fine intricate vascular network, 
they may consist entirely of cells with eosinophilic granular 
cytoplasm, particularly if high grade. On immunohistochem-
istry they characteristically co-express pan-cytokeratin and 
vimentin and are carbonic anhydrase IX (CA-IX) positive, 
but are usually Cytokeratin 7 (CK7) negative. The multi-
locular cystic renal neoplasm of low malignant potential was 
formerly included in the clear cell carcinoma category, but 
is now known to have indolent behaviour and an excellent 
prognosis, regardless of size, with no reported metastases 
[6, 28]. It is rare (< 1% of renal tumours), but is readily 
diagnosed if morphological criteria are strictly adhered to 
[1]. These cystic tumours characteristically have thin fibrous 
septae containing low-grade clear cells, but no solid expan-
sile clear cell nodules that are seen in clear cell RCC. They 
have been shown to have chromosome 3p deletions and VHL 
gene mutations similar to clear cell RCCs [1]. Correct patho-
logical diagnosis of these tumours is important, as they may 
be managed conservatively.
Papillary RCCs are grossly solid, with or without cystic 
change or encapsulation, and are often grey or brown in col-
our with a soft friable cut surface showing frequent necrosis 
and haemorrhage. On microscopy, according to the current 
WHO classification, they are divided into type 1 or type 2 
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tumours, determined primarily by their differing cytological 
features, and mixed patterns occur [1, 6, 29]. An oncocytic 
variant (composed of cells with abundant eosinophilic/pink 
cytoplasm) has also been described morphologically, but is 
included under the general category of papillary RCC in this 
classification system [1, 18].
Type 1 papillary RCCs usually consist of papillary struc-
tures lined by cuboidal cells with low-grade nuclei. Collec-
tions of foamy macrophages are often present within the 
papillary fibrovascular cores and calcifications (psammoma 
bodies) and intracellular haemosiderin are common. They 
may also show solid growth, with very compact papillary 
structures. The tumours have a typical profile on immuno-
histochemistry, including strong CK7 and alpha-methyla-
cyl-CoA racemase (AMACR) expression and at most focal 
CA-IX expression. At the molecular level, type 1 tumours 
typically show gains in chromosomes 7 and 17, and Y chro-
mosome loss. Most tumours are sporadic, but there are 
familial cases in the autosomal dominant hereditary papil-
lary RCC syndrome, where germline MET proto-oncogene 
mutations on chromosome 7 result in multiple bilateral 
tumours [30]. Extrarenal manifestations are not a feature 
of this familial syndrome [30]. Type 1 tumours generally 
present with a lower grade and stage at diagnosis and have a 
better outcome than type 2 tumours [31]. Tumours with the 
histological appearance of a non-encapsulated type 1 tumour 
and up to 15 mm in size are classified as papillary adenomas, 
rather than carcinomas, because they show benign clinical 
behaviour [1].
Morphologically, type 2 tumours have cells with more 
abundant eosinophilic cytoplasm that show nuclear pseu-
dostratification and higher grade nuclei. They also show 
more variable protein expression on immunohistochem-
istry than type 1 tumours, often including loss of CK7. 
At the molecular level, these tumours are associated with 
NRF2–ARE pathway activation and can be divided into 
several distinct molecular subtypes that are associated with 
differing patient survival. Papillary RCCs are now known to 
represent a much more heterogeneous group of tumours than 
implied by the 2016 WHO classification [32, 33]. A recent 
study by Saleeb et al. suggests that using a combination 
of morphological features, immunoprofiles and molecular 
analysis, papillary RCCs can be divided into four subtypes 
and that this type of grouping would be a better means of 
guiding patient management [34].
Papillary RCC is more often multifocal and bilateral than 
the other common tumour types, as seen in approximately 
10% of cases [6]. Papillary RCCs are also more frequent in 
acquired cystic kidney disease.
A less common tumour that may show overlapping mor-
phology with type 1 papillary RCCs, particularly in limited 
biopsy samples, is the mucinous tubular and spindle cell 
carcinoma (MTSCC) [1]. This is classically composed of 
elongated tubules and spindle cells, both cytologically low 
grade, and abundant intercellular mucin. It has a similar 
immunohistochemical profile to papillary RCCs, adding to 
the difficulty in distinguishing these tumours in some cases. 
Ren et al. have, however, demonstrated that MTSCCs show 
multiple chromosome losses and lack trisomy 7 and 17, ena-
bling separation on molecular studies [35]. These tumours 
are more common in females and generally exhibit indolent 
behaviour, but distant metastases have been reported [1, 18].
Chromophobe RCC is usually sporadic and generally has a 
good prognosis. Most of these tumours are confined to the 
kidney at diagnosis, though they may be large at the time 
of presentation [36]. They are characteristically tan in col-
our, similar to the benign renal oncocytoma that is the main 
differential diagnosis. On microscopy, chromophobe RCCs 
characteristically consist of large cells with prominent cell 
membranes, pale cytoplasm and crinkled ‘raisinoid’ nuclei 
with perinuclear halos. An eosinophilic variant also occurs, 
where the cells have an oncocytic cytoplasmic appearance 
and the nuclear features described are often less apparent. 
Chromophobe RCCs are characterised by multiple chromo-
some copy number alterations [37]. Hybrid oncocytic-chro-
mophobe tumours, with a mixed morphology, may occur 
sporadically or in the Birt–Hogg–Dubé syndrome. The lat-
ter shows autosomal dominant inheritance and is associated 
with FLCN gene mutations on chromosome 17 [6, 18, 26]. 
There are associated cutaneous lesions, pulmonary cysts 
and spontaneous pneumothoraces [30]. The hybrid renal 
tumours are usually small and show indolent behaviour and 
are amenable to conservative management [38]. A variety 
of other renal tumour types have also been reported in this 
syndrome [30].
Collecting duct carcinoma is a rare (1–2%) and highly 
aggressive type of RCC arising in the renal medulla. It may 
be difficult to distinguish histologically from urothelial car-
cinoma of the renal pelvicalyceal system, due to similar 
infiltrative high-grade variable morphology and their over-
lapping immunohistochemistry profiles. Distinction from 
metastatic tumours may also be problematic, particularly 
adenocarcinomas, and diagnosis is by exclusion of other 
entities. Metastatic disease is common at the time of diagno-
sis and the majority of patients do not survive 2 years from 
diagnosis [1, 18]. Renal medullary carcinoma has similar 
morphology and occurs in association with sickle cell trait 
or disease. This is rare, aggressive and occurs more often in 
younger adults. In contrast to collecting duct carcinomas, 
these tumours may express OCT3/4 on immunohistochemis-
try and show loss of expression of SMARCB1 (INI1) [1, 39].
MiT family translocation RCCs are rare and should be con-
sidered particularly in children and young adults presenting 
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with RCC, although they also occur in the adult population 
[40]. They result from gene fusions involving the MiT tran-
scription factor genes TFE3 and TFEB, with differing fusion 
partners. The best morphologically described tumours of the 
group are those associated with Xp11 and t(6;11) translo-
cations. The former may be recognised by their distinctive 
clear cell morphology with voluminous cells, and a pap-
illary architecture, sometimes with frequent calcifications 
(psammoma bodies). The less common t(6;11) translocation 
tumours have a characteristic biphasic pattern with distinct 
groups of large and small epithelioid cells. The MiT family 
translocation RCCs commonly show weak expression of epi-
thelial markers on immunohistochemistry and some express 
melanoma markers and cathepsin-K. Diagnosis requires 
fluorescence in situ hybridisation (FISH) to confirm the 
presence of the translocation, as use of immunohistochem-
istry has proven technically challenging. They may exhibit 
aggressive clinical behaviour, particularly in adults or those 
with the Xp11 translocation, and tend to develop early nodal 
metastases [1, 18, 36, 41]. They may be erroneously clas-
sified pathologically as clear cell RCCs, particularly when 
occurring in the adult population. This is of clinical signifi-
cance, as they may not respond to the vascular endothelial 
growth factor (VEGF)-targeted treatments.
Newly recognised types A number of provisional tumour 
types recognised at the 2012 ISUP Vancouver consensus 
meeting have been included as separate entities in the 2016 
WHO classification, as their morphology, immunoprofile 
and molecular characteristics are now better understood [1, 
6]. These include the clear cell papillary RCC that shows 
indolent behaviour, with no reported local recurrences or 
metastases, but would have been previously diagnosed as a 
clear cell RCC [42]. These are usually small tumours and 
are often cystic with compact tubulo-papillary solid areas. 
A distinctive morphological feature is the linear orientation 
of tumour cell nuclei away from the basement membranes, 
although a similar appearance may be seen focally in clear 
cell RCCs. On immunohistochemistry they are strongly CK7 
positive, unlike most clear cell RCCs, high molecular weight 
cytokeratin positive, AMACR negative and exhibit a dis-
tinct ‘cup-shaped’ staining pattern with CA-IX. Molecular 
studies show them to be distinct from clear cell and papil-
lary RCCs [1]. They occur sporadically or in association 
with acquired cystic renal disease and are now recognised 
as being the fourth most common type of renal cell car-
cinoma [42]. Another tumour occurring more frequently 
in the clinical setting of acquired cystic kidney disease is 
the acquired cystic kidney disease-associated RCC. These 
tumours usually show indolent behaviour unless exhibiting 
high-grade features. They often appear to arise within a cyst 
and are commonly multifocal and bilateral. Characteristic 
morphological features are a ‘sieve-like’ architecture and 
the presence of abundant oxalate crystals [1]. They are typi-
cally AMACR positive, but CK7 and CA-IX negative. They 
frequently occur with other renal tumour types [43].
Tubulocystic RCC is another rare, usually indolent, good 
prognosis tumour type more frequently seen in men. It was 
thought to be related to papillary RCCs, but is now accepted 
as a separate entity [1, 44]. It has a characteristic ‘bubble 
wrap’ appearance grossly, due to the presence of fibrotic 
stroma separating cystic spaces. Small tubules are present 
within the stroma microscopically and are lined by cells with 
eosinophilic cytoplasm and round nuclei with nucleoli of 
variable prominence. The tumour cells may also have a ‘hob-
nail’ appearance [1, 18]. These tumours express AMACR 
and CK7 on immunohistochemistry. On molecular analy-
sis, there have been conflicting reports, but in recent series 
of RCCs with a pure tubulocystic morphology, trisomy of 
chromosomes 7 and 17 observed in papillary RCCs was not 
present and these tumours have also been shown to have a 
molecular signature distinct from the more common RCC 
tumour types [45–47]. Other tumours may show areas with 
a tubulocystic pattern, including papillary RCCs, hereditary 
leiomyomatosis renal cell carcinoma-associated RCC, the 
MiT family translocation RCCs, collecting duct carcinoma 
and unclassified RCCs, causing diagnostic difficulty, but 
such tumours with mixed morphology are not included in 
this tumour category.
Hereditary tumours Less than 5% of renal cell carcinomas 
are associated with hereditary syndromes [30, 48]. In addi-
tion to those occurring in the previously described von Hip-
pel–Lindau, hereditary papillary renal cell carcinoma and 
Birt–Hogg–Dubé syndromes, there are also a number of 
more recently recognised hereditary renal tumours.
Succinate dehydrogenase-deficient RCC is rare and results 
from inherited germline mutations in the succinate dehy-
drogenase (SDH) gene, most commonly SDHB but also 
in SDHA, SDHC and SDHD. Affected patients may also 
present with paragangliomas and gastrointestinal stromal 
tumours (GISTs). The associated RCCs may be multifo-
cal and bilaterality occurs in around 25% of cases [49]. On 
microscopy, the RCCs are usually solid and are composed 
of cells with eosinophilic cytoplasm with distinctive cyto-
plasmic vacuolation and inclusions, although focal limited 
presence of these changes may hamper pathological recogni-
tion [50]. Intratumoral mast cells are also a common feature. 
Immunohistochemistry for demonstration SDHB is avail-
able, where a loss of staining is indicative of a mutation in 
the SDHB (most common), SDHC or SDHD genes. SDHA 
gene mutation can be demonstrated by additional absence 
of staining for SDHA. Most tumours are low grade and have 
a good prognosis, but those exhibiting high-grade features, 
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sarcomatoid morphology or necrosis may show aggressive 
behaviour, with a high rate of metastasis up to 70% [1, 50].
Patients with RCC associated with hereditary leiomy-
omatosis and renal cancer syndrome have an autosomal 
dominant inherited germline mutation in the FH gene on 
chromosome 1 that encodes for fumarate hydratase [26, 30]. 
This syndrome is also associated with cutaneous and uterine 
leiomyomata, occurring at greater frequency than the associ-
ated RCCs. These tumours are high grade and often have a 
papillary architecture, with tumour cells having eosinophilic 
cytoplasm. However, the morphology may be very variable 
and lead to misdiagnosis, for example, as an unclassified 
RCC, collecting duct carcinoma or type 2 papillary RCC, 
particularly as they may be solitary and, therefore, not sus-
pected to be part of a hereditary syndrome [51]. A char-
acteristic histological feature is the presence of distinctive 
prominent nucleoli with perinucleolar halos, exhibiting an 
appearance reminiscent of cytomegalovirus inclusions [52]. 
On immunohistochemistry, the combination of a lack of FH 
expression and overexpression of S-(2-succino)cysteine 
(2SC) suggests a diagnosis of FH-deficient RCC, which can 
then be confirmed with molecular studies. These are highly 
aggressive tumours, even when of small size, and show 
frequent distant metastases [30, 53]. Cases of FH-deficient 
RCC that are not obviously associated with the hereditary 
syndrome have been shown to have a similar presentation 
and clinical course. It has, therefore, been suggested that 
germline testing and counselling should also be undertaken 
in these cases when diagnosed pathologically [54, 55].
The tuberous sclerosis complex is associated with muta-
tions in the TSC1 (on chromosome 9) or TSC2 (on chromo-
some 16) genes encoding for hamartin or tuberin, respec-
tively, and shows autosomal dominant inheritance with 
variable penetrance. A variety of associated tumour types 
typically involve the skin, brain, retina, heart or kidney. The 
most common tumours in the kidneys are multiple angiomy-
olipomas, but RCC also occurs rarely and at a younger age 
than sporadic tumours [56, 57]. The RCCs in this syndrome 
have been described as exhibiting three differing morpho-
logical growth patterns: the most common are RCCs with 
prominent smooth muscle stroma and voluminous clear cells 
with a tubulopapillary growth pattern, and the others resem-
ble chromophobe-like RCCs or are similar to the sporadic 
eosinophilic solid and cystic RCC which is further described 
below [56]. The tumours show indolent behaviour. Previ-
ously undiagnosed tuberous sclerosis complex may be sus-
pected if such tumours are seen in combination with multiple 
angiomyolipomas.
Other tumour types There are several other tumour types 
that have been described in recent years, but are not cur-
rently recognised as separate entities in the WHO classi-
fication. The eosinophilic solid and cystic RCC is a rare 
tumour predominantly occurring in adult females, with a 
broad age range [58, 59]. Paediatric cases have also been 
described [60]. It occurs sporadically and is identical to a 
group of tumours occurring in patients with the tuberous 
sclerosis complex. Morphologically it is characterised by a 
solid and cystic growth pattern, with constituent cells having 
voluminous eosinophilic cytoplasm with prominent granular 
stippling. The tumour is distinct in frequently showing CK20 
positivity and typically a lack of expression of CA-IX and 
CK7. Limited molecular studies have demonstrated recur-
ring copy number alterations and TSC1 or TSC2 mutations 
in the sporadic tumours [59, 61, 62]. The tumours usually 
show indolent behaviour, but metastatic disease has been 
reported [60].
A number of other tumours of which there is limited 
experience at present include thyroid-like follicular RCCs, 
RCCs with angioleiomyomatous stroma, the oncocytic RCC 
that occurs post-neuroblastoma treatment and RCCs exhib-
iting ALK gene rearrangements, monosomy 8 and TCEB1 
mutations [1].
Unclassified RCC Approximately 5% of tumours remain 
difficult to categorise after thorough sampling and immu-
nohistochemical assessment, because the tumour is purely 
sarcomatoid, the immunoprofile is not definitive or there 
are unusual or overlapping morphological features. Tumours 
composed of eosinophilic cells have been shown to cause 
particular difficulty in classification when they do not show 
distinctive features [63]. Such tumours are placed in the 
‘unclassified’ category. This category will include both 
low- and high-grade tumours; therefore, pathologists are 
advised to describe the findings, so that it is clear in pathol-
ogy reports at which end of the grading spectrum the unclas-
sified tumour lies.
Challenges in tumour typing
Although most RCCs exhibit characteristic morphology that 
enables easy categorisation, with or without the assistance 
of routine immunohistochemistry, it is not uncommon for 
there to be difficulty in assigning a tumour type. RCCs show 
considerable morphological heterogeneity, with clear cells, 
oncocytic cells or a papillary architecture seen in a variety 
of renal tumours. A particularly problematic area is the sepa-
ration of oncocytic tumours, where benign and malignant 
entities may have overlapping morphology. It is well known 
that distinguishing a benign renal oncocytoma from a chro-
mophobe RCC may be difficult, particularly as fat invasion 
or vascular involvement, features normally associated with 
malignancy, does not necessarily exclude the diagnosis of 
an oncocytoma [64]. CK7 immunohistochemistry may help, 
as oncocytomas should show only focal staining whereas 
there is strong and diffuse staining in most chromophobe 
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RCCs. Fluorescence in situ hybridisation (FISH) can also 
be utilised, as multiple chromosome abnormalities typically 
occur in chromophobe RCCs, but this investigation is not 
necessarily routinely available. Even expert renal tumour 
pathologists report problems in this area, with only 64% of 
a group of world experts willing to definitively report benign 
oncocytomas on biopsy samples [65].
Panels of antibodies are used in immunohistochemistry 
to aid classification of tumours lacking typical morphology. 
However, routinely available antibodies do not exclusively 
stain one particular tumour type, thus creating diagnostic 
difficulty when the immunoprofile is not conclusive. In 
addition, some antibody stains may be positive adjacent to 
areas of necrosis, such as CA-IX or CK7, thus there may be 
aberrant staining in partly necrotic tumours in which these 
antibodies are usually negative, leading to misinterpretation 
of results.
Furthermore, high-grade tumours, particularly in a meta-
static setting, may lose characteristic morphological features 
and immunoprofiles, making confirmation of renal origin 
and tumour subtyping difficult. Pax-8 is helpful for deter-
mining renal origin, but is also positive in tumours from 
other sites, such as the thyroid gland and gynaecological 
tract tumours of Müllerian origin. Additionally, the rarity of 
some tumours, which may show only subtle morphological 
changes from the more common RCC types, makes it dif-
ficult to ensure that pathologists are able to recognise these 
unusual tumour types. In current practice, those tumours 
that do not exhibit sufficiently characteristic morphological 
features or immunoprofiles to allow confident categorisa-
tion into one of the known tumour types, therefore, remain 
‘unclassified’.
Tumour grade
The Fuhrman grading system, assessing nuclear and nucleo-
lar features, has been in international use for many years 
[66]. Although it has proven prognostic utility, intra- and 
inter-observer reproducibility has been problematic, due 
to difficulties in consistently applying the four grades as 
described morphologically [67–70]. A new WHO/ISUP 
grading system has been introduced following the conclu-
sions of the 2012 ISUP Vancouver conference and is recom-
mended for use by the WHO [1, 5]. This is also a four-grade 
system, with the degree of nucleolar prominence assessed 
to determine grades 1–3 and the presence of highly atypical 
‘pleomorphic’ cells and/or sarcomatoid or rhabdoid mor-
phology (see below) defining grade 4. The tumour grade is 
assigned according to the highest grade cells present, rather 
than the most predominant. In practice, the new WHO/ISUP 
grading, though similar to the Fuhrman system, is easier 
to apply and should be more reproducible and clinically 
relevant.
The WHO/ISUP grading system only applies to clear cell 
and papillary RCCs, as its prognostic utility has not been 
validated for other tumour types [67–70]. Although differ-
ent grading systems have been proposed for chromophobe 
RCC, to date, none have been internationally accepted for 
use in clinical practice [71, 72]. Collecting duct carcinomas 
are not graded, as by definition they are aggressive high-
grade tumours. Grading of RCCs should be more consistent 
following the introduction of the WHO/ISUP grading sys-
tem. However, grading is still subject to variation depending 
upon the extent of sampling of tumours, which may show 
only focal high-grade areas, and an individual pathologist’s 
microscopic assessment.
It has been proposed, though not formally accepted, that 
tumour necrosis should be incorporated into the WHO/ISUP 
grading system, to further refine the prognostic significance 
of tumour grades, as some studies have shown that the pres-
ence or absence of necrosis influences prognosis within a 
specific tumour grade [73, 74]. More recently, the prognostic 
relevance of the different morphological patterns observed in 
clear cell RCC has lead to the proposal of a different grading 
system based on tumour architecture [75].
Tumour necrosis
Tumour necrosis is included in prognostic algorithms for 
patient management, but only histological coagulative 
necrosis is recognised to have prognostic significance, as 
grossly visible tumour necrosis is possibly due to a differ-
ent mechanism (probable infarction due to the presence of 
tumour thrombus) [76]. Tumour necrosis has been shown 
to have prognostic significance for clear cell and chromo-
phobe RCCs, independent of tumour stage and grade [5, 22, 
77–79]. Papillary RCCs often contain areas of necrosis and 
its presence in this tumour type, therefore, lacks the same 
significance. However, a study of a series of type 1 papil-
lary RCCs by Peckova et al. demonstrated a good clinical 
outcome for cystic and extensively necrotic tumours [80]. 
Necrosis has also been shown to be an adverse prognos-
tic factor in t(6,11) translocation RCCs [81]. A study by 
Collins and Epstein of RCCs with extensive necrosis has, 
however, shown the situation to be more complex, with 
widespread cystic necrosis in high-grade tumours associated 
with a worse prognosis, but suggesting a good prognosis for 
low-grade tumours where the tumour type, grade and stage 
have greater prognostic significance [82]. Necrosis may also 
influence treatment efficacy, as, for example, the response 
to VEGF/tyrosine kinase inhibitor-targeted therapy has been 
shown to be poor in patients with metastatic disease where 
there was 10% or more necrosis in the primary clear cell 
RCC [83].
The quantity of tumour necrosis has been reported to 
affect the prognostic significance, not simply its presence 
World Journal of Urology 
1 3
[84–86]. However, although it has been recommended that 
the proportion of necrosis is recorded in histology reports, 
there is no international agreement as yet on how this can 
be reliably assessed pathologically [5].
Sarcomatoid and rhabdoid morphology
High-grade morphological features, such as the presence of 
cells with a sarcomatoid appearance, are associated with a 
poor outcome, with 15–22% 5-year survival reported and 
distant metastases commonly present at diagnosis (45–77%) 
[5, 87–90]. On histology, the most common pattern seen is 
a spindle cell sarcoma morphology; however, any pattern of 
sarcoma may be seen, including fibrosarcoma, chondrosar-
coma and many others [91]. This appearance may be pre-
sent in any of the main tumour types, occurring in approxi-
mately 5% of cases [5]. There is no minimum amount of 
sarcoma that needs to be seen to record this component. 
Tumours consisting only of sarcomatoid cells are placed in 
the ‘unclassified’ category in the WHO classification [1]. 
The extent of sarcomatoid morphology has been shown to 
adversely affect survival, but there is no international agree-
ment on how this can be measured and reported reliably 
[92, 93].
Rhabdoid morphology refers to the presence of large 
atypical cells with eccentric nuclei. Its presence is also 
reported to be associated with a poor prognosis [94–96]. 
It may occur in any RCC type, but is most commonly seen 
in clear cell RCCs [97]. At the molecular level, an asso-
ciation has been shown between the rhabdoid phenotype 
and alterations in the switch/sucrose nonfermentable (SWI/
SNF) chromatin modelling complex, similar to that noted in 
aggressive carcinomas from other sites exhibiting a rhabdoid 
or undifferentiated phenotype [98].
Sarcomatoid and rhabdoid cells may occur together and 
are both classified as WHO/ISUP grade 4 [1]. The presence 
of sarcomatoid morphology has, however, been shown to 
have a more significant association with death from RCC 
than the presence of rhabdoid morphology [99].
Tumour stage
Pathological tumour stage (TNM) is the most important 
prognostic factor for RCC and is derived from assessment 
of macroscopic and microscopic features [14, 100]. These 
include the tumour size and determination of the presence 
or absence of invasion into the perinephric fat, the renal 
sinus or Gerota’s fascia, involvement of the renal vein or 
inferior vena cava, direct invasion of or metastatic spread to 
the adrenal gland and lymph node metastases.
The 7th editions (TNM7) of the Union for International 
Cancer Control (UICC) and the American Joint Committee 
on Cancer (AJCC) TNM staging systems have been in use 
worldwide for over 7 years and have been validated in clini-
cal practice [101, 102].
Recently, the 8th editions (TNM8) of the alternative 
UICC and AJCC staging systems were published [103, 104]. 
Initially, there were a number of differences between the two 
in a range of tumour sites, including urological tumours, but 
following publication of errata, the pathological TNM stage 
is now closely aligned for renal tumours, although signifi-
cant differences still exist in the prognostic stage groupings 
[105, 106]. TNM8 has been recommended for use from 1st 
January 2018 [103, 104]. Although much of the TNM patho-
logical staging remains unchanged in TNM8, there are a few 
significant changes from TNM7 which are mentioned in the 
relevant sections below.
pT1 and pT2 Tumour size is part of TNM staging, with 40, 
70 and 100 mm being the boundary points for increasing 
stage categories (pT1a, pT1b and pT2a, respectively). The 
maximum diameter of the tumour (excluding any intravas-
cular extension), is assessed on macroscopic examination. 
For localised clear cell RCC, tumour size has been shown 
to correlate with clinical outcome, with increasing tumour 
size correlating with a worse prognosis [107]. Most tumours 
that exceed a maximum of 70 mm diameter show renal sinus 
involvement (fat or vascular invasion) and are, therefore, of 
higher stage [108].
pT3 The presence of perinephric fat invasion is part of TNM 
staging (pT3a). The nature of the invasive edge, whether 
pushing (rounded) or infiltrative, has been shown to have 
prognostic significance, with 3-year survival rates of 75% 
and 27%, respectively, although specification of the growth 
pattern is not currently a required item for pathology reports 
[109].
Renal sinus invasion, defined as invasion into sinus fat/
connective tissue or within vascular spaces, is the principal 
route of extra-renal spread of RCCs (pT3a). Through the 
extensive work of Bonsib, it is now recognised as a vital 
area for pathological assessment to ensure accurate staging 
[110–112]. The presence of renal sinus invasion has been 
shown to be associated with more aggressive tumour behav-
iour than perinephric fat invasion [113].
Only gross invasion of the renal vein or its ‘muscle con-
taining segmental branches’ is included in TNM7 stage 
pT3a. However, for TNM8, the requirement for ‘gross’ 
invasion is removed, as is the need for involved branches 
(tributaries) of the renal vein to contain muscle. The TNM8 
pT3a stage, therefore, includes the presence of any involve-
ment of the renal vein and its branches, whether identified 
grossly or microscopically.
Invasion of the pelvicalyceal system has been shown in 
some studies, including a meta-analysis involving over 9000 
patients, to be associated with poor survival and to reduce 
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recurrence-free survival [114–117]. It is not part of TNM7 
staging, but is included in TNM8 as pT3a.
pT3b is defined as involvement of the inferior vena cava 
(IVC) below the diaphragm and pT3c as IVC involvement 
above the diaphragm or if there is evidence of direct invasion 
of the vein wall at any level. In TNM8, the need for the IVC 
involvement to be visible grossly has been removed.
pT4 The presence of direct invasion of the ipsilateral adrenal 
gland has a poor outcome and is TNM stage pT4 [78, 84]. It 
is present in 2% of cases at nephrectomy and is more often 
seen in large tumours, those in the upper pole or those with 
vascular invasion [118]. Invasion of Gerota’s fascia, taken 
as the surgical margin of the fat at nephrectomy, is also pT4.
pN Palpable lymph nodes are found in the hilar region in 
less than 10% of nephrectomy cases [119]. Although sur-
vival rates fall progressively as the number of lymph nodes 
involved by metastatic tumour increases, the TNM staging 
has only two categories for regional node status: pN1 for 
one or more positive nodes and pN0 if they are uninvolved.
pM pM1 is the category assigned for pathologically proven 
distant metastases. Adrenal metastases are stage pM1, as 
are nodal metastases beyond the regional lymph nodes or at 
other distant sites.
Lymphovascular invasion
Lymphovascular (microvascular) invasion (other than that 
within the perinephric or renal sinus fat in stage pT3a) is 
not part of TNM staging. However, it has been reported to 
correlate with survival, independent of tumour size, grade 
or type, and to have prognostic significance in low-stage 
RCC, independent of tumour grade [120–123]. Lymphatic 
spread to hilar lymph nodes is less often seen in clear cell 
RCCs than in papillary RCCs or collecting duct carcinomas.
Surgical margins
All surgical margins are assessed routinely in pathol-
ogy, with margin involvement by tumour being generally 
regarded as a risk factor for local tumour recurrence. Patients 
with residual disease post-nephrectomy have poorer survival 
[124]. The presence of invasion of the renal vein wall at 
the surgical margin of the vein is also a risk factor for local 
recurrence [125]. Assessment of the parenchymal surgical 
margin is of importance for partial nephrectomy specimens, 
although one large study of over 3800 cases has shown a lack 
of correlation between the presence of a positive surgical 
margin and tumour recurrence [126].
Potential future improvements
Biomarkers
There is a need to develop more reliable and readily avail-
able biomarkers for immunohistochemistry that have diag-
nostic, predictive and prognostic utility. Similarly, devel-
opment of validated molecular tests and pathways for easy 
access to this advancing technology is necessary. Such 
tests need to be able to overcome the heterogeneity of renal 
tumours that affects grading and molecular characteristics in 
different regions of the tumour. Development of molecular 
tumour profiles may enable prediction of behaviour of those 
tumours for which the current WHO/ISUP grading system 
is not applicable or might obviate the need for microscopic 
assessment of tumour grade.
Any new tests need to be applicable to small biopsy sam-
ples. Biopsies of renal masses or metastases are becoming 
more frequent, being used to guide management of small 
renal masses and systemic treatments of metastatic disease. 
When an adequate sample has been achieved, renal biopsies 
have been shown to be highly sensitive and specific, with 
low complication rates [127, 128]. However, such samples, 
by virtue of the limited amount of tissue available and the 
heterogeneity of renal tumours, do pose problems with path-
ological diagnosis, tumour typing and assessment of grade 
[129, 130]. There is, therefore, a need to develop validated 
methods of utilising these small amounts of tumour tissue to 
obtain information critical for patient management.
Education and improved referral pathways
Many nephrectomy and biopsy specimens will be reported 
outside specialist centres. It is, therefore, crucial that 
pathologists in the wider community are able to recognise 
less familiar tumour types that potentially influence patient 
prognosis and management or have genetic implications. 
In the UK, for example, there is a national uropathology 
external quality assessment (EQA) scheme (www.histo patho 
logye qa.org) which has an educational role in improving 
standards. Pathologists are expected to participate in EQA 
schemes relevant to their areas of clinical practice, regularly 
assessing slides and receiving feedback on their performance 
in comparison with their peers. This type of activity and the 
availability of educational courses, guidelines and online 
resources have significantly improved knowledge of renal 
tumour pathology. Nonetheless, infrequent tumour types 
may be misdiagnosed. Referral for expert opinion is always 
an option, initiated by the reporting pathologist, but it is sug-
gested that for specific cases, such as tumours occurring in 
younger adults, or where there is a family history or presence 
of multiple tumours, there should be automatic referral to 
a specialist centre for pathology review. This is particularly 
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important where further FISH or molecular tests are deemed 
necessary.
Digital pathology
The advent of rapid whole-slide scanning technology, ena-
bling the production of high-resolution and high-quality 2D 
and 3D digital images from conventional glass slides, has 
brought with it considerable opportunities for the future 
practice of renal tumour pathology, as well as pathology 
as a whole.
In clinical practice, there are the potential advantages of 
remote reporting and for obtaining rapid second opinions, 
without the need for costly and time-consuming transpor-
tation of glass slides between laboratories. Work may be 
distributed digitally, from centres with staff shortages, to 
pathologists available at geographically distant centres, thus 
maintaining reporting turnaround times [131]. For rarer 
renal tumour entities, it is possible for pathologists to share 
images and to obtain rapid expert opinions from around the 
world. Case review for multidisciplinary team meetings is 
facilitated by enabling images to be shared across a number 
of centres simultaneously. Digital macroscopic and micro-
scopic images of specimens can also be incorporated into 
pathology reports and stored on hospital patient information 
systems.
Image analysis techniques have the potential to remove 
subjectivity and inter-observer variation from, for example, 
tumour grading, by enabling digital assessment of nucleolar 
size and nuclear features. The development of computer-
assisted diagnostics also enables automated assessment of 
morphological features, either to highlight areas of inter-
est to the pathologist, such as the highest grade areas of 
tumours, or to identify subtle features of prognostic signifi-
cance or predictive of response to therapy [132–134].
Immunohistochemistry for biomarker evaluation in 
research, either on series of tumour sections or on tissue 
microarrays, involves assessment of the intensity and distri-
bution of protein expression, often on a very large number 
of tumours. This is very laborious and time-consuming work 
and is subject to considerable inter- and intra-observer varia-
tion. Image analysis systems have the capability of not only 
speeding up analysis and handling high volumes, but may 
also remove the element of subjectivity inherent in manual 
assessment [135]. There is also potential for simultaneous 
assessment of multiple biomarkers on the same tissue sec-
tion. Pathologist input is, however, paramount for ensuring 
that the correct tissue area is assessed. Such technology is 
also potentially advantageous in clinical practice, as the 
introduction of any additional biomarker assessments adds 
work to an already stretched specialty [136].
For clinical trials, involving large numbers of centres, 
there is the opportunity to centrally review digital images 
of tumour samples, for quality assurance, and to maintain 
a central image library of cases for future analysis [137].
For teaching and education, digital pathology is also 
highly effective. ISUP now has an image database for uro-
logical pathology, which can be accessed online (www.isup.
org) and provides an invaluable resource of renal tumour 
images for reference and promotes standardisation of diag-
nosis and tumour grading [138, 139]. The capacity to anno-
tate digital images enhances the educational value.
The wider availability of digital pathology for diagnostic 
use will, however, require significant investment in equip-
ment, provision of efficient storage and retrieval facilities 
for the immense number of generated digital images, and for 
staff training. There is also a need to introduce guidelines 
and quality assurance checks to enable widespread use in 
clinical practice [140, 141]. Ultimately, it will require a cul-
ture change in the way pathology is practised in the future.
Conclusion
In recent years, there has been considerable progress in pro-
ducing guidance for pathologists in the assessment of renal 
tumours, thus improving consistency in diagnosis, grading 
and staging. The development of additional immunohisto-
chemical and molecular tests is needed to facilitate tumour 
typing, because of prognostic implications, and to enable 
more reliable identification of poorly differentiated meta-
static tumours as being of renal origin. Any new tests need 
to be applicable to small biopsy samples, to overcome the 
heterogeneity of renal tumours. There is also a need to facili-
tate identification of tumour types that have genetic implica-
tions. This may mean automatic referral of certain categories 
of patient or tumours to specialist centres or establishing 
national referral centres for expert review and further tests. 
Digital pathology has a potential role in facilitating such 
referral practice.
Tumour grading has established prognostic significance, 
but it is still based upon subjective microscopic assessment 
and the extent of tumour sampling. It is also not applicable 
to all renal tumour types. The WHO/ISUP system has advan-
tages over the former Fuhrman grading system, but finding 
ways of improving assignment of grade, enhancing its rel-
evance, or introducing an alternative means of categorising 
tumours is also important for future patient management.
Author contributions AYW: project development, data collection, data 
analysis, manuscript writing and editing. DH: data analysis and editing
Compliance with ethical standards 
Conflict of interest The authors declare that they have no relevant con-
flicts of interest.
 World Journal of Urology
1 3
Research involving human participants and/or animals The following 
manuscript is a review of existing data. Therefore, this article does not 
contain any studies with human participants or animals performed by 
any of the authors.
Informed consent For this type of study (review) formal consent is 
not required.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. International Agency for Research on Cancer (2016) WHO 
classification of tumours of the urinary system and male genital 
organs (IARC WHO classification of tumours), 4th edn. WHO/
IARC Press, Lyon
 2. Algaba F, Delahunt B, Berney DM, Camparo P, Compérat E, 
Griffiths D et al (2012) Handling and reporting of nephrectomy 
specimens for adult renal tumours: a survey by the European 
Network of Uropathology. J Clin Pathol 65:106–113
 3. Delahunt B, Srigley JR, Montironi R, Egevad L (2014) Advances 
in renal neoplasia: recommendations from the 2012 International 
Society of Urological Pathology Consensus Conference. Urology 
83:969–974
 4. Delahunt B, Egevad L, Montironi R, Srigley JR (2013) Interna-
tional Society of Urological Pathology (ISUP) consensus confer-
ence on renal neoplasia: rationale and organization. Am J Surg 
Pathol 37:1463–1468
 5. Delahunt B, Cheville JC, Martignoni G, Humphrey PA, Magi-
Galluzzi C, McKenney J et al (2013) The International Society 
of Urological Pathology (ISUP) grading system for renal cell 
carcinoma and other prognostic parameters. Am J Surg Pathol 
37:1490–1504
 6. Srigley JR, Delahunt B, Eble JN, Egevad L, Epstein JI, Grignon 
D et al (2013) The International Society of Urological Pathology 
(ISUP) Vancouver classification of renal neoplasia. Am J Surg 
Pathol 37:1469–1489
 7. Tan PH, Cheng L, Rioux-Leclercq N, Merino MJ, Netto G, 
Reuter VE et al (2013) Renal tumors: diagnostic and prognostic 
biomarkers. Am J Surg Pathol 37:1518–1531
 8. Trpkov K, Grignon DJ, Bonsib SM, Amin MB, Billis A, Lopez-
Beltran A et al (2013) Handling and staging of renal cell carci-
noma: the International Society of Urological Pathology Con-
sensus (ISUP) conference recommendations. Am J Surg Pathol 
37:1505–1517
 9. Reuter VE, Argani P, Zhou M, Delahunt B, Members of the 
ISUP Immunohistochemistry in Diagnostic Urologic Pathology 
Group (2014) Best practices recommendations in the application 
of immunohistochemistry in the kidney tumors: report from the 
International Society of Urologic Pathology consensus confer-
ence. Am J Surg Pathol 38:e35–e49
 10. Amin MB, Epstein JI, Ulbright TM, Humphrey PA, Egevad L, 
Montironi R et al (2014) Best practices recommendations in the 
application of immunohistochemistry in urologic pathology: 
report from the International Society of Urological Pathology 
consensus conference. Am J Surg Pathol 38:1017–1022
 11. Delahunt B, Srigley J, Amin M, Billis A, Camparo P, Evans A 
et al (2017) Invasive carcinoma of renal tubular origin, histopa-
thology reporting guide, 1st edn. International Collaboration on 
Cancer Reporting, Sydney
 12. Delahunt B, Srigley J, Amin M, Billis A, Camparo P, Evans A 
et al (2017) Renal biopsy for tumour, histopathology reporting 
guide, 1st edn. International Collaboration on Cancer Reporting, 
Sydney
 13. Warren AY, Griffiths D, Fleming S (2017) Dataset for histo-
pathological reporting of adult renal parenchyma neoplasms, 
3rd edn. The Royal College of Pathologists, London
 14. Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch 
MJ (2000) Prognostic utility of the recently recommended his-
tologic classification and revised TNM staging system of renal 
cell carcinoma: a Swiss experience with 588 tumors. Cancer 
89:604–614
 15. Ljungberg B, Alamdari FI, Stenling R, Roos G (1999) Prognostic 
significance of the Heidelberg classification of renal cell carci-
noma. Eur Urol 36:565–569
 16. Murphy WM, Grignon DJ, Perlman EJ (2004) Tumours of 
the kidney, bladder and related urinary structures, vol 4. AFIP 
atlas of tumour pathology. American Registry of Pathology, 
Washington
 17. Kim H, Cho NH, Kim DS, Kwon YM, Kim EK, Rha SH et al 
(2004) Renal cell carcinoma in South Korea: a multicenter study. 
Hum Pathol 35:1556–1563
 18. Srigley JR, Delahunt B (2009) Uncommon and recently described 
renal carcinomas. Mod Pathol 22:S2–S23
 19. Novara G, Ficarra V, Antonelli A, Artibani W, Bertini R, Carini 
M et al (2010) Validation of the 2009 TNM version in a large 
multi-institutional cohort of patients treated for renal cell carci-
noma: are further improvements needed? Eur Urol 58:588–595
 20. Leibovich BC, Lohse CM, Crispen PL, Boorjian SA, Thompson 
RH, Blute ML et al (2010) Histological subtype is an independ-
ent predictor of outcome for patients with renal cell carcinoma. 
J Urol 183:1309–1315
 21. O’Brien MF, Russo P, Motzer RJ (2008) Sunitinib therapy in 
renal cell carcinoma. BJU Int 101:1339–1342
 22. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML 
(2003) Comparisons of outcome and prognostic features among 
histologic subtypes of renal cell carcinoma. Am J Surg Pathol 
27:612–624
 23. Steffens S, Roos FC, Janssen M, Becker F, Steinestel J, Abbas 
M et al (2014) Clinical behaviour of chromophobe renal cell 
carcinoma is less aggressive than that of clear cell renal cell car-
cinoma, independent of Fuhrman grade or tumor size. Virchows 
Arch 465:439–444
 24. Amin MB, Amin MB, Tamboli P, Javidan J, Stricker H, de Ven-
turina MP et al (2002) Prognostic impact of histologic subtypes 
of adult renal epithelial neoplasms: an experience of 405 cases. 
Am J Surg Pathol 26:281–291
 25. Nickerson ML, Jaeger E, Shi Y, Durocher JA, Mahurkart S, 
Zaridze D et al (2008) Improved identification of von Hippel-
Lindau gene alterations in clear cell renal tumours. Clin Cancer 
Res 14:4726–4734
 26. Maher ER (2018) Hereditary renal cell carcinoma syndromes: 
diagnosis, surveillance and management. World J Urol. https ://
doi.org/10.1007/s0034 5-018-2288-5. [Epub ahead of print]
 27. Taneja K, Arora S, Rogers CG, Gupta NS, Williamson SR (2018) 
Pathologic staging of renal cell carcinoma: a review of 300 con-
secutive cases with emphasis on retrograde venous invasion. His-
topathology https ://doi.org/10.1111/his.13672 . [Epub ahead of 
print]
 28. Bhatt JR, Jewett MA, Richard PO, Kawaguchi S, Timilshina N, 
Evans A et al (2016) Multilocular cystic renal cell carcinoma: 
World Journal of Urology 
1 3
pathological T staging makes no difference to favourable out-
comes and should be reclassified. J Urol 196(5):1350–1355
 29. Delahunt B, Eble JN (1997) Papillary renal cell carcinoma: 
a clinicopathologic and immunohistochemical study of 105 
tumors. Mod Pathol 10:537–544
 30. Adeniran AJ, Shuch B, Humphrey PA (2015) Hereditary renal 
cell carcinoma syndromes. Clinical, pathologic and genetic fea-
tures. Am J Surg Pathol 39(12):e1–e18
 31. Delahunt B, Eble JN, McCredie MR, Bethwaite PB, Stewart JH, 
Bilous AM (2001) Morphologic typing of papillary renal cell 
carcinoma: comparison of growth kinetics and patient survival 
in 66 cases. Hum Pathol 32:590–595
 32. Cancer Genome Atlas Research Network, Linehan WM, Spell-
man PT, Ricketts CJ, Creighton CJ et al (2016) Comprehensive 
molecular characterisation of papillary renal cell carcinomas. N 
Engl J Med 374(2):135–145
 33. Flippot R, Comperat E, Tannir NM, Maloaf GG (2018) Papillary 
renal cell carcinoma: a family portrait. Eur Urol 73:79–80
 34. Saleeb RM, Brimo F, Farag M, Rompré-Brodeur A, Rotondo 
F, Beharry V (2017) Toward biological subtyping of papillary 
renal cell carcinoma with clinical implications through histo-
logic, immunohistochemical and molecular analysis. Am J Surg 
Pathol 41:1618–1629
 35. Ren Q, Wang L, Al-Ahmadie HA, Fine SW, Gopalan A, Sirin-
trapun SJ et al (2018) Distinct genomic copy number alterations 
distinguish mucinous tubular and spindle cell carcinoma of the 
kidney from papillary renal cell carcinoma with overlapping his-
tologic features. Am J Surg Pathol 42(6):767–777
 36. Shuch B, Amin A, Armstrong AJ, Eble JN, Ficarra V, Lopez-
Beltran A et al (2015) Understanding pathologic variants of renal 
cell carcinoma: distilling therapeutic opportunities from biologic 
complexity. Eur Urol 67:85–97
 37. Tan MH, Wong CF, Tan HL, Yang XJ, Ditley J, Matsuda D et al 
(2010) Genomic expression and single nucleotide polymorphism 
profiling discriminates chromophobe renal cell carcinoma and 
oncocytoma. BMC Cancer 10:196
 38. Pavlovich CP, Walther MM, Eyler RA, Hewitt SM, Zbar B, 
Linehan WM et al (2002) Renal tumors in the Birt-Hogg-Dubé 
syndrome. Am J Surg Pathol 26:1542–1552
 39. Ohe C, Smith SC, Sirohi D, Divatia M, de Peralta-Venturina M, 
Paner GP et al (2018) Reappraisal of morphologic differences 
between renal medullary carcinoma, collecting duct carcinoma 
and fumarate hydratase-deficient renal cell carcinoma. Am J Surg 
Pathol 42:279–292
 40. Argani P (2015) MiT family translocation renal cell carcinomas. 
Semin Diagn Pathol 32:103–113
 41. Cutruzzula P, Cahn D, Kivlin D, Tong C, Edwards D, Amster 
M (2016) A review of translocation t(6;11) renal cell carcinoma 
tumours in the adult patient. Curr Urol 10:69–71
 42. Zhou H, Zheng S, Truong LD, Ro JY, Ayala AG, Shen SS (2014) 
Clear cell papillary renal cell carcinoma is the fourth most com-
mon histological type of renal cell carcinomas in 290 consecutive 
nephrectomies for renal cell carcinoma. Hum Pathol 45:59–64
 43. Przybycin CG, Harper HL, Reynolds JP, Magi-Galluzzi C, 
Nguyen JK, Wu A et al (2018) Acquired cystic disease-associated 
renal cell carcinoma (ACD-RCC): a multiinstitutional study of 40 
cases with clinical follow-up. Am J Surg Pathol 42:1156–1165. 
https ://doi.org/10.1097/pas.00000 00000 00109 1 [Epub ahead of 
print]
 44. Amin MB, MacLennan GT, Gupta R, Grignon D, Paraf F, 
Vieillefond A et al (2009) Tubulocystic carcinoma of the kid-
ney: clinicopathologic analysis of 31 cases of a distinctive rare 
subtype of renal cell carcinoma. Am J Surg Pathol 33:384–392
 45. Tran T, Jones CL, Williamson SR, Eble JN, Grignon DJ, Zhang 
S et al (2016) Tubulocystic renal cell carcinoma is an entity that 
is immunohistochemically and genetically distinct from papillary 
renal cell carcinoma. Histopathology 68:850–857
 46. Zhang P, Yang X, Yu L, Wu Y, Wang C (2017) Tubulocystic 
renal cell carcinoma of the kidney: a clinical, pathological, 
immunohistochemical, and fluorescence in situ hybridization 
study. Int J Clin Exp Pathol 10(3):3327–3334
 47. Lawrie CH, Armesto M, Fernandez-Mercado M, Arestin M, 
Manterola L, Goicoechea I (2018) Noncoding RNA expression 
and targeted next-generation sequencing distinguish tubulocystic 
renal cell carcinoma (TC-RCC) and other renal neoplasms. J Mol 
Diagn 20(1):34–45
 48. Menko FH, Maher ER (2016) Diagnostic and management 
of hereditary renal cell cancer. Recent Results Cancer Res 
205:85–104
 49. Gill AJ (2018) Succinate dehydrogenase (SDH)-deficient neo-
plasia. Histopathology 72:106–116
 50. Williamson SR, Eble JN, Amin MB, Gupta NS, Smith SC, Sholl 
LM et al (2015) Succinate dehydrogenase-deficient renal cell car-
cinoma: detailed characterisation of 11 tumors defining a unique 
subtype of renal cell carcinoma. Mod Pathol 28:80–94
 51. Chen Y-B, Brannon R, Toubaji A, Dudas ME, Won HH, Al-
Ahmadie HA et al (2014) Hereditary leiomyomatosis and renal 
cell carcinoma syndrome-associated renal cancer: recognition 
of the syndrome by pathologic features and the utility of detect-
ing aberrant succination by immunohistochemistry. Am J Surg 
Pathol 38(5):627–637
 52. Merino MJ, Torres-Cabala C, Pinto P, Lineman WM (2007) The 
morphological spectrum of kidney tumours in hereditary leio-
myomatosis and renal cell carcinoma (HLRCC) syndrome. Am 
J Surg Pathol 31:1578–1585
 53. Grubb RL 3rd, Franks ME, Toro J, Middleton L, Choyke L, 
Fowler S et al (2007) Hereditary leiomyomatosis and renal cell 
cancer: a syndrome associated with an aggressive form of inher-
ited renal cancer. J Urol 177:2074–2079
 54. Trpkov K, Hes O, Agaimy A, Bonert M, Martinek P, Magi-
Galluzzi C et al (2016) Fumarate hydratase-deficient renal cell 
carcinoma is strongly correlated with fumarate hydratase muta-
tion and hereditary leiomyomatosis and renal cell carcinoma 
syndrome. Am J Surg Pathol 40(7):865–875
 55. Smith SC, Trpkov K, Chen Y-B, Mehra R, Sirohi D, Ohe C et al 
(2016) Tubulocystic carcinoma of the kidney with poorly dif-
ferentiated foci: a frequent morphological pattern of fumarate 
hydratase-deficient renal cell carcinoma. Am J Surg Pathol 
40(11):1457–1472
 56. Guo J, Tretiakova MS, Troxwell ML, Osunkoya AO, Fadare O, 
Sangoi AR et al (2014) Tuberous sclerosis-associated renal cell 
carcinoma. A clinicopathological study of 57 separate carcino-
mas in 18 patients. Am J Surg Pathol 38(11):1457–1467
 57. Yang P, Cornejo KM, Sadow PM, Cheng L, Wang M, Xiao Y 
et al (2014) Renal cell carcinoma in tuberous sclerosis complex. 
Am J Surg Pathol 38:895–909
 58. Trpkov K, Hes O, Bonert M, Lopez JI, Bonsib SM, Nesi G et al 
(2016) Eosinophilic solid and cystic renal cell carcinoma. Clin-
icopathological study of 16 unique sporadic neoplasms occurring 
in women. Am J Surg Pathol 40(1):60–71
 59. Trpkov K, Abou-Ouf H, Hes O, Lopez JI, Nesi G, Comperat E, 
Sibony M et al (2017) Eosinophilic solid and cystic renal cell 
carcinoma (ESC RCC). Further morphologic and molecular char-
acterisation of ESC RCC as a distinct entity. Am J Surg Pathol 
41(10):1299–1308
 60. Li Y, Reuter VE, Matoso A, Netto GJ, Epstein JI, Argani P 
(2018) Re-evaluation of 33 ‘unclassified’ eosinophilic renal cell 
carcinomas in young patients. Histopathology 72:588–600
 61. Palsgrove DN, Li Y, Pratilas C, Lin MT, Pallavajjalla A, Gocke 
C et al (2018) Eosinophilic solid and cystic (ESC) renal cell 
carcinomas harbour TSC mutations: molecular analysis supports 
 World Journal of Urology
1 3
an expanding clinicopathological spectrum. Am J Surg Pathol 
42:1166–1181. https ://doi.org/10.1097/pas.00000 00000 00111 1 
[Epub ahead of print]
 62. Parilla M, Kadri S, Patil SA, Ritterhouse L, Segal J, Henriksen 
KJ et al (2018) Are sporadic eosinophilic solid and cystic renal 
cell carcinomas characterised by somatic tuberous sclerosis gene 
mutations? Am J Surg Pathol 42(7):911–917
 63. Perrino CM, Grignon DJ, Williamson SR, Idrees MT, Eble JN, 
Cheng L (2018) Morphological spectrum of renal cell carci-
noma, unclassified: an analysis of 136 cases. Histopathology 
72(2):305–319
 64. Kryvenko ON, Jorda M, Argani P, Epstein J (2014) Diagnostic 
approach to eosinophilic renal neoplasms. Arch Pathol Lab Med 
138(11):1531–1541
 65. Williamson SR, Gadde R, Trpkov K, Hirsch MS, Srigley JR, 
Reuter VE et al (2017) Diagnostic criteria for oncocytic renal 
neoplasms: a survey of urologic pathologists. Hum Pathol 
63:149–156
 66. Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance 
of morphologic parameters in renal cell carcinoma. Am J Surg 
Pathol 6:655–663
 67. Sika-Paotonu D, Bethwaite PB, McCredie MR, William Jordan 
T, Delahunt B (2006) Nucleolar grade but not Fuhrman grade is 
applicable to papillary renal cell carcinoma. Am J Surg Pathol 
30:1091–1096
 68. Delahunt B (2009) Advances and controversies in grading and 
staging of renal cell carcinoma. Mod Pathol 22:S24–S36
 69. Delahunt B, Sika-Paotonu D, Bethwaite PB, McCredie MR, Mar-
tignoni G, Eble JN et al (2007) Fuhrman grading is not appro-
priate for chromophobe renal cell carcinoma. Am J Surg Pathol 
31:957–960
 70. Delahunt B, Sika-Paotonu D, Bethwaite PB, William Jordan T, 
Magi-Galluzzi C, Zhou M et al (2011) Grading of clear cell renal 
cell carcinoma should be based on nucleolar prominence. Am J 
Surg Pathol 35:1134–1139
 71. Finley DS, Shuch B, Said JW, Galliano G, Jeffries RA, Afifi 
AA et al (2011) The chromophobe tumor grading system is the 
preferred grading scheme for chromophobe renal cell carcinoma. 
J Urol 186:2168–2174
 72. Paner GP, Amin MB, Alvarado-Cabrero I, Young AN, Stricker 
HJ, Moch H et al (2010) A novel tumor grading scheme for chro-
mophobe renal cell carcinoma: prognostic utility and comparison 
with Fuhrman nuclear grade. Am J Surg Pathol 34:1233–1240
 73. Delahunt B, McKenney JK, Lohse CM, Leibovich BC, Thomp-
son RH, Boorjian SA et al (2013) A novel grading system for 
clear cell renal cell carcinoma incorporating tumor necrosis. Am 
J Surg Pathol 37:311–322
 74. Khor LY, Dhakal HP, Jia X, Reynolds JP, McKenney JK, Rini 
BI et al (2016) Tumor necrosis adds prognostically significant 
information to grade in clear cell renal cell carcinoma: a study of 
842 consecutive cases from a single institution. Am J Surg Pathol 
40:1224–1231
 75. Verine J, Colin D, Nheb M, Prapotnich D, Ploussard G, Cathelin-
eau X et al (2018) Architectural patterns are a relevant morpho-
logic grading system for clear cell renal cell carcinoma prognosis 
assessment. Am J Surg Pathol 42(4):423–441
 76. Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon 
ED et al (2003) Prediction of progression after radical nephrec-
tomy for patients with clear cell renal cell carcinoma: a stratifica-
tion tool for prospective clinical trials. Cancer 97:1663–1671
 77. Amtrup F, Hansen JB, Thybo E (1974) Prognosis in renal carci-
noma evaluated from histological criteria. Scand J Urol Nephrol 
8:198–202
 78. Thompson RH, Cheville JC, Lohse CM, Webster WS, Zincke H, 
Kwon ED et al (2005) Reclassification of patients with pT3 and 
pT4 renal cell carcinoma improves prognostic accuracy. Cancer 
104:53–60
 79. Sengupta S, Lohse CM, Leibovich BC, Frank I, Thompson RH, 
Webster WS et al (2005) Histologic coagulative tumor necrosis 
as a prognostic indicator of renal cell carcinoma aggressiveness. 
Cancer 104:511–520
 80. Peckova K, Martinek P, Pivovarcikova K, Vanecek T, Alaghe-
hbandan R, Prochazkova K et al (2017) Cystic and necrotic papil-
lary renal cell carcinoma: prognosis, morphology, immunohisto-
chemical and molecular-genetic profile of 10 cases. Ann Diagn 
Pathol 26:23–30
 81. Peckova K, Vanecek T, Martinek P, Spangnolo D, Kurdoda N, 
Brunelli M et al (2014) Aggressive and nonaggressive transloca-
tion t(6;11) renal cell carcinoma: comparative study of 6 cases 
and review of the literature. Ann Diagn Pathol 18:351–357
 82. Collins J, Epstein JI (2017) Prognostic significance of extensive 
necrosis in renal cell carcinoma. Hum Pathol 66:108–114
 83. Park JY, Lee JL, Baek S, Eo SH, Go H, Ro JY et al (2014) Sar-
comatoid features, necrosis, and grade are prognostic factors in 
metastatic clear cell renal cell carcinoma with vascular endothe-
lial growth factor-targeted therapy. Hum Pathol 45(7):1437–1444
 84. Ficarra V, Novara G, Iafrate M, Cappellaro L, Bratti E, Zattoni 
F et al (2007) Proposal for reclassification of the TNM stag-
ing system in patients with locally advanced (pT3–4) renal cell 
carcinoma according to the cancer-related outcome. Eur Urol 
51:722–729
 85. Klatte T, Said JW, de Martino M, Larochelle J, Shuch B, Rao 
JY et al (2009) Presence of tumor necrosis is not a significant 
predictor of survival in clear cell renal cell carcinoma: higher 
prognostic accuracy of extent based rather than presence/absence 
classification. J Urol 181:1558–1564
 86. Renshaw AA, Cheville JC (2015) Quantitative tumour necrosis 
is an independent predictor of overall survival in clear cell renal 
cell carcinoma. Pathology 47:34–37
 87. Cheville JC, Lohse CM, Zincke H, Weaver AL, Leibovich BC, 
Frank I et al (2004) Sarcomatoid renal cell carcinoma: an exami-
nation of underlying histologic subtype and an analysis of asso-
ciations with patient outcome. Am J Surg Pathol 28:435–441
 88. Cangiano T, Liao J, Naitoh J, Dorey F, Figlin R, Belldegrun 
A (1999) Sarcomatoid renal cell carcinoma: biologic behavior, 
prognosis, and response to combined surgical resection and 
immunotherapy. J Clin Oncol 17:523–528
 89. Delahunt B (1999) Sarcomatoid renal carcinoma: the final com-
mon dedifferentiation pathway of renal epithelial malignancies. 
Pathology 31:185–190
 90. de Peralta-Venturina M, Moch H, Amin M, Tamboli P, Haile-
mariam S, Mihatsch M et al (2001) Sarcomatoid differentiation 
in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol 
25:275–284
 91. Lebacle C, Pooli A, Bessede T, Irani J, Pantuck AJ, Drakaki 
A (2018) Epidemiology, biology and treatment of sarcoma-
toid RCC: current state of the art. World J Urol. https ://doi.
org/10.1007/s0034 5-018-2355
 92. Zhang BY, Thompson RH, Lohse CM, Leibovich BC, Boor-
jian SA, Cheville JC et al (2015) A novel prognostic model 
for patients with sarcomatoid renal cell carcinoma. BJU Int 
115:405–411
 93. Adibi M, Thomas AZ, Borregales LD, Merrill MM, Slack RS, 
Chen HC et al (2015) Percentage of sarcomatoid component as 
a prognostic indicator for survival in renal cell carcinoma with 
sarcomatoid dedifferentiation. Urol Oncol 33:e17–e23
 94. Kuroiwa K, Kinoshita Y, Shiratsuchi H, Oshiro Y, Tamiya S, Oda 
Y et al (2002) Renal cell carcinoma with rhabdoid features: an 
aggressive neoplasm. Histopathology 41:538–548
World Journal of Urology 
1 3
 95. Gökden N, Nappi O, Swanson PE, Pfeifer JD, Vollmer RT, Wick 
MR et al (2000) Renal cell carcinoma with rhabdoid features. Am 
J Surg Pathol 24:1329–1338
 96. Przybycin CG, McKenney JK, Reynolds JP, Campbell S, Zhou 
M, Karafa MT et al (2014) Rhabdoid differentiation is associ-
ated with aggressive behaviour in renal cell carcinoma: a clin-
icopathological analysis of 76 cases with clinical follow-up. Am 
J Surg Pathol 38(9):1260–1265
 97. Leroy X, Zini L, Buob D, Ballereau C, Villers A, Aubert S 
(2007) Renal cell carcinoma with rhabdoid features: an aggres-
sive neoplasm with overexpression of p53. Arch Pathol Lab Med 
131:102–106
 98. Agaimy A, Cheng L, Egevad L, Feyerabend B, Hes O, Keck B 
et al (2017) Rhabdoid and undifferentiated phenotype in renal 
cell carcinoma: analysis of 32 cases indicating a distinctive com-
mon pathway of dedifferentiation frequently associated with 
SWI/SNF complex deficiency. Am J Surg Pathol 41(2):253–262
 99. Zhang BY, Cheville JC, Thompson RH, Lohse CM, Boojian SA, 
Leibovich BC et al (2015) Impact of rhabdoid differentiation on 
prognosis for patients with grade four renal cell carcinoma. Eur 
Urol 68:5–7
 100. Bonsib SM (2008) Macroscopic assessment, dissection protocols 
and histologic sampling strategy for renal cell carcinomas. Diagn 
Histopathol 14:151–156
 101. Sobin LH, Gospodarowicz MK, Wittekind C (2009) TNM clas-
sification of malignant tumours (UICC International Union 
Against Cancer), 7th edn. Wiley-Blackwell, Oxford
 102. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti 
A (2011) AJCC cancer staging manual, 7th edn. Springer, New 
York
 103. Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, 
Washington MK et al (2016) AJCC cancer staging manual, 8th 
edn. Springer, New York
 104. Brierley JD, Gospodarowicz MK, Wittekind C (2017) TNM 
classification of malignant tumours, 8th edn. Wiley-Blackwell, 
Hoboken
 105. Delahunt B, Egevad L, Samaratunga H, Varma M, Verrill C, 
Cheville J et al (2017) UICC drops the ball in the 8th edition 
TNM staging of urological cancers. Histopathology 71:5–11
 106. Paner GP, Stadler WM, Hansel DE, Montironi R, Lin DW, Amin 
MB (2018) Updates in the eighth edition of the tumor-node-
metastasis staging classification for urologic cancers. Eur Urol 
73(4):560–569
 107. Delahunt B, Kittelson JM, McCredie MR, Reeve AE, Stewart 
JH, Bilous AM (2002) Prognostic importance of tumor size for 
localized conventional (clear cell) renal cell carcinoma: assess-
ment of TNM T1 and T2 tumor categories and comparison with 
other prognostic parameters. Cancer 94:658–664
 108. Bonsib SM (2005) T2 clear cell renal cell carcinoma is a rare 
entity: a study of 120 clear cell renal cell carcinomas. J Urol 
174:1199–1202
 109. Thomas DH, Verghese A, Kynaston HG, Griffiths DF (2003) 
Analysis of the prognostic implications of different tumour mar-
gin types in renal cell carcinoma. Histopathology 43:374–380
 110. Bonsib SM, Gibson D, Mhoon M, Greene GF (2000) Renal 
sinus involvement in renal cell carcinomas. Am J Surg Pathol 
24:451–458
 111. Bonsib SM (2006) Renal lymphatics, and lymphatic involvement 
in sinus vein invasive (pT3b) clear cell renal cell carcinoma: a 
study of 40 cases. Mod Pathol 19:746–753
 112. Bonsib SM (2007) Renal veins and venous extension in clear cell 
renal cell carcinoma. Mod Pathol 20:44–53
 113. Thompson RH, Leibovich BC, Cheville JC, Webster WS, Lohse 
CM, Kwon ED et al (2005) Is renal sinus fat invasion the same 
as perinephric fat invasion for pT3a renal cell carcinoma? J Urol 
174:1218–1221
 114. Bailey GC, Boorjian SA, Ziegelmann MJ, Westerman ME, Lohse 
CM, Leibovich BC et al (2017) Urinary collecting system inva-
sion is associated with poor survival in patients with clear-cell 
renal cell carcinoma. BJU Int 119:585–590
 115. Chen L, Ma X, Li H, Li X, Gao Y, Zhang Y et al (2016) Invasion 
of the urinary collecting system is an independent prognostic 
factor in pT3 renal cell carcinoma. Urol Oncol 34:e11–e16
 116. Verhoest G, Avakian R, Bensalah K, Thuret R, Ficarra V, Arti-
bani W et al (2009) Urinary collecting system invasion is an 
independent prognostic factor of organ confined renal cell carci-
noma. J Urol 182:854–859
 117. Chen L, Li H, Gu L, Ma X, Li X, Zhang F et al (2016) Prognostic 
role of urinary collecting system invasion in renal cell carcinoma: 
a systematic review and meta-analysis. Sci Rep 6:21325
 118. O’Malley RL, Godoy G, Kanofsky JA, Taneja SS (2009) The 
necessity of adrenalectomy at the time of radical nephrectomy: 
a systematic review. J Urol 181:2009–2017
 119. Saitoh H, Nakayama M, Nakamura K, Satoh T (1982) Distant 
metastasis of renal adenocarcinoma in nephrectomized cases. J 
Urol 127:1092–1095
 120. Madbouly K, Al-Qahtani SM, Ghazwani Y, Al-Shaibani S, Mansi 
MK (2007) Microvascular tumor invasion: prognostic signifi-
cance in low-stage renal cell carcinoma. Urology 69:670–674
 121. Lang H, Lindner V, Letourneux H, Martin M, Saussine C, Jac-
qmin D (2004) Prognostic value of microscopic venous inva-
sion in renal cell carcinoma: long-term follow-up. Eur Urol 
46:331–335
 122. Griffiths DF, Verghese A, Golash A, Kynaston HG, Matthews 
PN, Hart AJ et al (2002) Contribution of grade, vascular invasion 
and age to outcome in clinically localized renal cell carcinoma. 
BJU Int 90:26–31
 123. Kroeger N, Rampersaud EN, Patard JJ, Klatte T, Birkhäuser FD, 
Shariat SF et al (2012) Prognostic value of microvascular inva-
sion in predicting the cancer specific survival and risk of meta-
static disease in renal cell carcinoma: a multicenter investigation. 
J Urol 187:418–423
 124. Karellas M, Jang T, Kagiwada M, Kinnaman M, Jarnagin W, 
Russo P (2009) Advanced-stage renal cell carcinoma treated by 
radical nephrectomy and adjacent organ or structure resection. 
BJU Int 103:160–164
 125. Liu N, Wren J, Vertosick E, Lee J, Power N, Benfante N et al 
(2016) The prognostic impact of a positive vascular margin on 
pT3 clear cell renal cell carcinoma. J Urol 195:264–269
 126. Antic T, Taxy JB (2015) Partial nephrectomy for renal tumors: 
lack of correlation between margin status and local recurrence. 
Am J Clin Pathol 143:645–651
 127. Patel H, Johnson M, Pierorazio P, Sozio S, Sharma R, Iyoha 
E et al (2016) Diagnostic accuracy and risks of biopsy in the 
diagnosis of a renal mass suspicious for localized renal cell carci-
noma: systematic review of the literature. J Urol 195:1340–1347
 128. Jeon H, Seo S, Jeong B, Jeon S, Lee H, Choi H et al (2016) 
Percutaneous kidney biopsy for a small renal mass: a critical 
appraisal of results. J Urol 195:568–573
 129. Delahunt B, Samaratunga H, Martignoni G, Srigley J, Evans A, 
Brunelli M (2014) Percutaneous renal tumour biopsy. Histopa-
thology 65:295–308
 130. Evans A, Delahunt B, Srigley J (2015) Issues and challenges 
associated with classifying neoplasms in percutaneous needle 
biopsies of incidentally found small renal masses. Semin Diagn 
Pathol 32:184–195
 131. Williams BJ, Bottoms D, Treanor D (2017) Future-proofing 
pathology: the case for clinical adoption of digital pathology. J 
Clin Pathol 70:1010–1081
 World Journal of Urology
1 3
 132. Mezheyeuski A, Hrynchyk I, Karlberg M, Portyanko A, Egevad 
L, Ragnhammar P et al (2016) Image analysis-derived metrics of 
histomorphological complexity predicts prognosis and treatment 
response in stage II–III colon cancer. Sci Rep 6:36149. https ://
doi.org/10.1038/srep3 6149
 133. Jansen I, Lucas M, Savci-Heijink CD, Meijer SL, Marquering 
HA, de Bruin DM et al (2018) Histopathology: ditch the slides, 
because digital and 3D are on show. World J Urol 36:549–555
 134. Raza Ali H, Dariush A, Provenzano E, Bardwell H, Abraham 
JE, Iddawela M et al (2016) Computational pathology of pre-
treatment biopsies identifies lymphocyte density as a predictor 
of response to neoadjuvant chemotherapy in breast cancer. Breast 
Cancer Res 18:21
 135. Hamilton PW, Bankhead P, Wang Y, Hutchinson R, Kieran D, 
McArt DG et al (2014) Automated analysis for molecular profil-
ing in lung cancer. Methods 70:59–73
 136. Koelzer VH, Gisler A, Hanhart JC, Griss J, Wagner SN, Willi 
N et al (2018) Digital image analysis improves precision of 
programmed death ligand 1 (PD-L1) scoring in cutaneous 
melanoma. Histopathology https ://doi.org/10.1111/his.13528 
[Epub ahead of print]
 137. Mroz P, Parwani A, Kulesza P (2013) Central pathology review 
for phase III clinical trials. The enabling effect of virtual micros-
copy. Arch Pathol Lab Med 137:492–495
 138. Egevad L, Cheville J, Evans AJ, Hörnblad J, Kench JG, Kris-
tiansen G et al (2017) Pathology imagebase—a reference image 
database for standardisation of pathology. Histopathology 
71(5):677–685
 139. Egevad L, Delahunt B, Berney DM, Bostwick DG, Cheville 
J, Comperat E et al (2018) Utility of pathology imagebase for 
standardisation of prostate cancer grading. Histopathology 7:8–
18. https ://doi.org/10.1111/his.13471 [Epub ahead of print]
 140. Griffin J, Treanor D (2017) Digital pathology in clinical use: 
where are we now and what is holding us back? Histopathology 
70:134–145
 141. Cross S, Furness P, Igali L, Snead D, Treanor D (2018) Best 
practice recommendations for implementing digital pathology. 
The Royal College of Pathologists, London
